Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exact Sciences Completes Modular PMA For Cologuard

This article was originally published in The Gray Sheet

Executive Summary

The molecular diagnostics manufacturer submitted the final module of its PMA for Cologuard and expects to request Medicare coverage later this year through the FDA-CMS parallel review process.

You may also be interested in...

Research Briefs: Studies From Exact Sciences, EndoChoice; Neuroimaging Overuse

In the lead up to an FDA panel, positive data is published for Exact Science’s Cologuard multi-target stool DNA-based screening test. EndoChoice’s Fuse endoscope sees more colon cancer than traditional endoscopes. Overuse of neuroimaging for headaches documented. Long-term study finds high-frequency oscillatory ventilation is better for premature babies than standard ventilation. Drug-coated balloon trial.

News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay

Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.

Research In Brief

Exact Sciences’ and Genomic Health announce favorable results for colon cancer tests. Boston Scientific launches trial of MRI-safe pacemaker. More research news.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts